ClinicalTrials.gg
RecruitingNCT07823283Updated Sep 21, 2026

Continuous Monitoring of Microvascular Anastomoses: An Observational Trial

An observational study in Head and Neck Neoplasm, sponsored by Mayo Clinic. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-21.

Sponsored by Mayo Clinic · Observational

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Head and Neck Neoplasms by Mayo Clinic — 4 open to participants now, 4 under way, 1 of them phase 3. Head and Neck Neoplasms · Mayo Clinic.

Started
2026
the only one that year
Observational
9 of 17
2 open now
Registered
17th of 17
by date

Among the 17 studies in Head and Neck Neoplasms by Mayo Clinic, this one is the only one that started in 2026, is one of 9 observational ones, and was the 17th registered.

Head and Neck Neoplasms

2,718 studies on the registry are indexed under Head and Neck Neoplasms; 599 are open to participants now.

Browse Head and Neck Neoplasms studies →

Open to participants now

4 of the 17 studies in Head and Neck Neoplasms by Mayo Clinic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 458 Head and Neck Neoplasms studies recruiting now, 350 (76%) set no upper age limit and 51 (11%) stop at 75 or younger; 22 take children under 18; 27 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Head and Neck Neoplasms by Mayo Clinic, or all of them as a file.
02

Study summary

This study is being done to see whether signals from a device that monitors blood flow through the free flap can be recorded and converted from an audible signal, like a heartbeat, into a visual signal. Researchers plan to use this information to ultimately help surgeons and care teams monitor free flaps to try to prevent flap failure.

03

Conditions studied

  • Head and Neck Neoplasm
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients scheduled to undergo free flap surgery with an implantable doppler

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Scheduled for free flap surgery and planned to have an implanted doppler monitor
  • Arterial Doppler waveforms available for analysis
  • Able and willing to sign consent and return for clinical follow up
  • Age ≥ 18 years

Exclusion criteria

Exclusion Criteria:

  • Prior head and neck surgery within the region where surgeons plan to identify donor vessels ≤ 365 days prior to registration
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)

Groups and cohorts

  • Observational

    Patients undergo recording of the clinical Doppler monitor via an implanted research recording device (RRD) and have their medical records reviewed on study.

    Other: Non-Interventional Study

Interventions

  • OtherNon-Interventional Study

    Non-interventional study

    Also known as: Non-Interventional Observational Study, Noninterventional (Observational) Study

06

What researchers measure

Primary outcomes

  1. Feasibility - record audible doppler signal tracings

    Ability to record a minimum of 2 audible doppler signal tracings from the implantable doppler per 24 hours for a minimum of one 24 hour period for 80% of subjects. Analysis of the primary endpoint will be done in a binary (yes/no) fashion to describe the feasibility of the proposed research recording device (RRD) to record and convert recorded signals into various visual formats. Recordings will be observed by study staff to determine whether auditory acuity matches expected signals.

    Time frame: Up to 30 days

  2. Feasibility - convert audible doppler signal tracings to stored data files

    Ability to convert the recorded doppler signal tracings to stored data files for 80% of subjects. Analysis of the primary endpoint will be done in a binary (yes/no) fashion to describe the feasibility of the proposed RRD to record and convert recorded signals into various visual formats.

    Time frame: Up to 30 days

Secondary outcomes

  1. Feasibility - convert audible data to visual signal to a visual signal

    Ability to convert a minimum of 80% of the audible data files to a visual signal. Analysis of the primary endpoint will be done in a binary (yes/no) fashion to describe the feasibility of the proposed RRD to record and convert recorded signals into various visual formats. Visual displays will be observed by study staff to confirm the display matches the expected form, as informed by prior experience/literature with doppler studies of peripheral vasculature. The specific methods for visualization will include a multimodal approach that includes Doppler signal time-series waveform, spectrogram, and Fourier Transform.

    Time frame: Up to 30 days

Other outcomes

  1. AI algorithm

    Ability to build a predictive artificial intelligence (AI) algorithm for identifying high-risk or compromised flaps using a neural network.

    Time frame: Up to 2 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Sep 2028, 24 months after the start.

Of 216 non-industry observational studies under Head and Neck Neoplasms, half reached primary completion within 71 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 144. This study's planned 24 months is below that.

Counting every sponsor, half of 238 studies reached it within 69 months; a quarter within 29 and three quarters within 144.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2026
First posted
Sep 16, 2026
StartActual
Sep 17, 2026
Primary completionEst.
Sep 30, 2028
CompletionEst.
Sep 30, 2028
Last update
Sep 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07823283
Lead sponsor
Mayo Clinic
Responsible party
Sponsor
First posted
Sep 16, 2026
Start date
Sep 17, 2026
Primary completion
Sep 30, 2028 (estimated)
Completion
Sep 30, 2028 (estimated)
Last update
Sep 21, 2026

Study contacts

Clinical Trials Referral Office
Contact
mayocliniccancerstudies@mayo.edu
855-776-0015
Colleen Dickman
Contact
507-284-1231
Kathryn M. Van Abel, MD
principal investigator · Mayo Clinic in Rochester

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion